Advertisement





Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2003; 42:882-888, doi:10.1016/S0735-1097(03)00855-6
© 2003 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Maron, B. J.
Right arrow Articles by Aeppli, D. M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Maron, B. J.
Right arrow Articles by Aeppli, D. M.

CLINICAL RESEARCH

Clinical course of hypertrophiccardiomyopathy with survival to advanced age

Barry J. Maron, MD, FACC*,*, Susan A. Casey, RN*, Robert G. Hauser, MD, FACC* and Dorothee M. Aeppli, PhD{dagger}

* Hypertrophic Cardiomyopathy Center, Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, USA
{dagger} Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA

Manuscript received January 20, 2003; revised manuscript received April 11, 2003, accepted May 21, 2003.

* Reprint requests and correspondence: Dr. Barry J. Maron, Minneapolis Heart Institute Foundation, 920 E. 28th Street, Suite 60, Minneapolis, Minnesota 55407, USA.
hcm.maron{at}mhif.org

OBJECTIVES: This study was designed to clarify and resolve the clinical profile of older patients with hypertrophic cardiomyopathy (HCM).

BACKGROUND: Adverse consequences of HCM such as sudden death and incapacitating symptoms have been emphasized for the young and middle-aged.

METHODS: Long-term outcome of HCM was assessed in a community-based cohort not subject to tertiary center referral bias.

RESULTS: Of 312 patients, 73 (23%) achieved normal life expectancy (≥75 years; range to 96); 44 (14%) were ≥80 years old. Most patients ≥75 years (47; 64%) experienced no or only mild limiting symptoms and lived virtually their entire lives with few HCM-related clinical consequences; 26 patients (36%) experienced severe progressive symptoms. In elderly patients with HCM, diagnosis and symptom onset were considerably delayed to 74 ± 8 and 70 ± 11 years, respectively. For patients ≥50 years at diagnosis, the probability of survival for 5, 10, and 15 years was 85 ± 3%, 74 ± 4%, and 57 ± 6%, respectively, and did not significantly differ from a matched general population (p = 0.20). Patients ≥75 years were predominantly women, and had less marked wall thickness and more frequently showed basal outflow obstruction ≥30 mm Hg (compared with those <75 years; p < 0.01 and 0.001, respectively).

CONCLUSIONS: Hypertrophic cardiomyopathy is frequently well tolerated and compatible with normal life expectancy, and may remain clinically dormant for long periods of time with symptoms and initial diagnosis deferred until late in life. These observations afford a measure of reassurance to many patients with HCM, a disease for which clinical course is often unfavorable and unpredictable.

Abbreviations and Acronyms
  HCM
  hypertrophic cardiomyopathy
  HF
  heart failure
  LV
  left ventricle




This article has been cited by other articles:


Home page
Heart AsiaHome page
B B Siswanto and R Aryani
Recent advances in diagnosis and management of hypertrophic cardiomyopathy
Heart Asia, March 1, 2009; 2009(3): 1 - 4.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
A. Nasermoaddeli, K. Miura, A. Matsumori, Y. Soyama, Y. Morikawa, A. Kitabatake, Y. Inaba, and H. Nakagawa
Prognosis and prognostic factors in patients with hypertrophic cardiomyopathy in Japan: results from a nationwide study
Heart, June 1, 2007; 93(6): 711 - 715.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
A. Sarikas, L. Carrier, C. Schenke, D. Doll, J. Flavigny, K. S. Lindenberg, T. Eschenhagen, and O. Zolk
Impairment of the ubiquitin-proteasome system by truncated cardiac myosin binding protein C mutants
Cardiovasc Res, April 1, 2005; 66(1): 33 - 44.
[Abstract] [Full Text] [PDF]



 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement